title: Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
abstract: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease. We created a LRRK2 transgenic mouse model that recapitulates cardinal features of the disease: an age-dependent and levodopa-responsive slowness of movement associated with diminished dopamine release and axonal pathology of nigrostriatal dopaminergic projection. These mice provide a valid model of Parkinson's disease and are a resource for the investigation of pathogenesis and therapeutics.
authors.affiliation: Department of Neurology and Neurosciences, Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Yanping
authors.initials: Y
authors.lastname: Li
authors.forename: Wencheng
authors.initials: W
authors.lastname: Liu
authors.forename: Tinmarla F
authors.initials: TF
authors.lastname: Oo
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Tang
authors.forename: Vernice
authors.initials: V
authors.lastname: Jackson-Lewis
authors.forename: Chun
authors.initials: C
authors.lastname: Zhou
authors.forename: Kindiya
authors.initials: K
authors.lastname: Geghman
authors.forename: Mikhail
authors.initials: M
authors.lastname: Bogdanov
authors.forename: Serge
authors.initials: S
authors.lastname: Przedborski
authors.forename: M Flint
authors.initials: MF
authors.lastname: Beal
authors.forename: Robert E
authors.initials: RE
authors.lastname: Burke
authors.forename: Chenjian
authors.initials: C
authors.lastname: Li
mesh_terms: D000367:Age Factors; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D022202:Chromosomes, Artificial, Bacterial; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D018014:Gene Transfer Techniques; D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D007980:Levodopa / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D009069:Movement Disorders / Q000188:drug therapy / Q000235:genetics; D020125:Mutation, Missense; D009474:Neurons / Q000473:pathology / Q000502:physiology; D009627:Nomifensine / Q000494:pharmacology; D010300:Parkinson Disease / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D018765:Dopamine Uptake Inhibitors; D009627:Nomifensine; D007980:Levodopa; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases; D001058:Apomorphine; D004298:Dopamine